Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 8.4% in the third quarter, HoldingsChannel.com reports. The firm owned 30,024 shares of the company’s stock after buying an additional 2,329 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Nurix Therapeutics were worth $675,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Geode Capital Management LLC increased its position in shares of Nurix Therapeutics by 9.6% in the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company’s stock valued at $32,544,000 after buying an additional 126,306 shares in the last quarter. Barclays PLC lifted its position in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after buying an additional 56,190 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Nurix Therapeutics in the 3rd quarter valued at $346,000. EP Wealth Advisors LLC purchased a new stake in Nurix Therapeutics in the 3rd quarter worth $240,000. Finally, Wellington Management Group LLP increased its holdings in Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock worth $78,243,000 after acquiring an additional 280,240 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $546,680.16. The trade was a 18.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 3,546 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the sale, the chief financial officer now owns 33,724 shares in the company, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,401 shares of company stock valued at $437,453 in the last 90 days. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Trading Down 4.4 %

NRIX opened at $20.24 on Thursday. The stock’s 50-day moving average price is $23.58 and its 200 day moving average price is $22.28. Nurix Therapeutics, Inc. has a 12-month low of $7.65 and a 12-month high of $29.56. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.96 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on NRIX. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Oppenheimer raised their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. HC Wainwright boosted their price objective on Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird started coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 target price for the company. Finally, Royal Bank of Canada lowered their price target on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.35.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.